Huntington Disease - Pipeline Review, H2 2019

December 2019 | 345 pages | ID: HC9ECBACE820EN
Global Markets Direct

Abstracts

Huntington Disease - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Pipeline Review, H2 2019, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 10, 13, 57, 16 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 3 molecules, respectively.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Huntington Disease - Overview
Huntington Disease - Therapeutics Development
Huntington Disease - Therapeutics Assessment
Huntington Disease - Companies Involved in Therapeutics Development
Huntington Disease - Drug Profiles
Huntington Disease - Dormant Projects
Huntington Disease - Discontinued Products
Huntington Disease - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Huntington Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Huntington Disease - Pipeline by Active Biotech AB, H2 2019
Huntington Disease - Dormant Projects, H2 2019
Huntington Disease - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Huntington Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

Active Biotech AB
AcuraStem Inc
Addex Therapeutics Ltd
Adeptio Pharmaceuticals Ltd
AFFiRiS AG
Alkermes Plc
Allianz Pharmascience Ltd
Alsonex Pty Ltd
Anima Biotech Inc
Annexon Inc
Armgo Pharma Inc
ArunA Biomedical Inc
Asklepios BioPharmaceutical Inc
Avergen Pharmaceuticals GmbH
Azevan Pharmaceuticals Inc
BrainStorm Cell Therapeutics Inc
Brainvectis SAS
BridgeBio Pharma Inc
Celon Pharma SA
Chaperone Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Cleave Therapeutics Inc
Collaborative Medicinal Development LLC
Curyx Bio Inc
DanPET AB
Dystrogen Therapeutics SA
Emerald Health Sciences Inc
Evotec SE
Exicure Inc
F. Hoffmann-La Roche Ltd
Genervon Biopharmaceuticals LLC
Hope Biosciences LLC
Immungenetics AG
Krisani Bio Sciences Pvt Ltd
Living Cell Technologies Ltd
Locana Inc
Medesis Pharma SA
MindImmune Therapeutics Inc
Mitochon Pharmaceuticals Inc
Mitoconix Bio Ltd
Mitokinin LLC
MMJ International Holdings Corp
Navitor Pharmaceuticals Inc
NeuBase Therapeutics Inc
NeuExcell Therapeutics Inc
Neurimmune Holding AG
Neurodon LLC
NeuroNascent Inc
New World Laboratories Inc
NLS Pharma Group
Novartis AG
Nuredis Inc
Omeros Corp
Ophidion Inc
Oryzon Genomics SA
Oscine Therapeutics
Oxalys Pharmaceuticals Inc
PharmatrophiX Inc
Priavoid GmbH
Primary Peptides Inc
ProQR Therapeutics NV
Prous Institute for Biomedical Research SA
PTC Therapeutics Inc
reMYND NV
Resilio Therapeutics LLC
Retrotope Inc
Sage Therapeutics Inc
Secura Bio Inc
Seneb BioSciences Inc
Shinkei Therapeutics LLC
SOM Biotech SL
Sosei Heptares
Spark Therapeutics Inc
Stealth BioTherapeutics Corp
T3D Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Thelial Technologies SA
TreeFrog Therapeutics SAS
Ultragenyx Pharmaceutical Inc
UniQure NV
Vaccinex Inc
Vitality Biopharma Inc
Vivoryon Therapeutics AG
Voyager Therapeutics Inc
Vybion Inc
Wave Life Sciences Ltd